Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor Drugs
Background. To explore clinical characteristics and treatment reasons for intravitreal injection of antivascular endothelial growth factor (anti-VEGF) drugs in the treatment of nontype 1 retinopathy of prematurity (ROP). Methods. A retrospective study was conducted to screen the nontype 1 ROP from t...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2022/6266528 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567743010832384 |
|---|---|
| author | Haitao Zhang Xin Yang Fangfang Zheng Xiangke Yin Suhua Wan |
| author_facet | Haitao Zhang Xin Yang Fangfang Zheng Xiangke Yin Suhua Wan |
| author_sort | Haitao Zhang |
| collection | DOAJ |
| description | Background. To explore clinical characteristics and treatment reasons for intravitreal injection of antivascular endothelial growth factor (anti-VEGF) drugs in the treatment of nontype 1 retinopathy of prematurity (ROP). Methods. A retrospective study was conducted to screen the nontype 1 ROP from the collected ROP patients who received intravitreal injections of anti-VEGF drugs in Henan Eye Hospital from September 2018 to June 2021. Results. A total of 138 ROP cases (262 eyes) were included in this study, including 39 cases (28.3%), 65 eyes (24.8%) that were the nontype 1 ROP. Compared with the type 1 ROP group, the nontype 1 ROP group had slightly later treatment time (39.8 ± 2.7 weeks vs 38.1 ± 2.6 weeks, P<0.05) and a higher proportion of fusion protein drugs (87.2% vs 54.5%, P<0.05). After intravitreal injection of anti-VEGF drugs, 27 eyes (41.5%) were cured and 38 eyes (58.5%) improved in the nontype 1 ROP group, without recurrence and aggravation cases. There were more lesions in zone II (63 eyes, 96.9%), with stage 2 (40 eyes, 61.5%) and stage 3 (23 eyes, 35.4%), and 58 eyes (89.2%) showed preplus in the nontype 1 ROP group. Treatment reasons included preplus in 58 eyes (89.2%), ridge aggravation in 22 eyes (33.8%), simultaneous treatment of the contralateral eye in 9 eyes (13.8%), no regression of lesions in the persistent stage 2 or 3 over PMA 44 weeks of follow-up in 8 eyes (12.3%), and logistical considerations in 4 eyes (6.2%). Conclusions. Considering some peculiar clinical characteristics, treatment by intravitreal injection of anti-VEGF drugs may be considered carefully for some nontype 1 ROP in critical conditions. |
| format | Article |
| id | doaj-art-96226c9646ab4eb8981ac22177b879ca |
| institution | Kabale University |
| issn | 2090-0058 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-96226c9646ab4eb8981ac22177b879ca2025-02-03T01:00:43ZengWileyJournal of Ophthalmology2090-00582022-01-01202210.1155/2022/6266528Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor DrugsHaitao Zhang0Xin Yang1Fangfang Zheng2Xiangke Yin3Suhua Wan4Henan Provincial People’s HospitalHenan Provincial People’s HospitalNeonatal Intensive Care Unit of Henan Provincial People’s HospitalHenan Provincial People’s HospitalHenan Provincial People’s HospitalBackground. To explore clinical characteristics and treatment reasons for intravitreal injection of antivascular endothelial growth factor (anti-VEGF) drugs in the treatment of nontype 1 retinopathy of prematurity (ROP). Methods. A retrospective study was conducted to screen the nontype 1 ROP from the collected ROP patients who received intravitreal injections of anti-VEGF drugs in Henan Eye Hospital from September 2018 to June 2021. Results. A total of 138 ROP cases (262 eyes) were included in this study, including 39 cases (28.3%), 65 eyes (24.8%) that were the nontype 1 ROP. Compared with the type 1 ROP group, the nontype 1 ROP group had slightly later treatment time (39.8 ± 2.7 weeks vs 38.1 ± 2.6 weeks, P<0.05) and a higher proportion of fusion protein drugs (87.2% vs 54.5%, P<0.05). After intravitreal injection of anti-VEGF drugs, 27 eyes (41.5%) were cured and 38 eyes (58.5%) improved in the nontype 1 ROP group, without recurrence and aggravation cases. There were more lesions in zone II (63 eyes, 96.9%), with stage 2 (40 eyes, 61.5%) and stage 3 (23 eyes, 35.4%), and 58 eyes (89.2%) showed preplus in the nontype 1 ROP group. Treatment reasons included preplus in 58 eyes (89.2%), ridge aggravation in 22 eyes (33.8%), simultaneous treatment of the contralateral eye in 9 eyes (13.8%), no regression of lesions in the persistent stage 2 or 3 over PMA 44 weeks of follow-up in 8 eyes (12.3%), and logistical considerations in 4 eyes (6.2%). Conclusions. Considering some peculiar clinical characteristics, treatment by intravitreal injection of anti-VEGF drugs may be considered carefully for some nontype 1 ROP in critical conditions.http://dx.doi.org/10.1155/2022/6266528 |
| spellingShingle | Haitao Zhang Xin Yang Fangfang Zheng Xiangke Yin Suhua Wan Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor Drugs Journal of Ophthalmology |
| title | Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor Drugs |
| title_full | Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor Drugs |
| title_fullStr | Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor Drugs |
| title_full_unstemmed | Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor Drugs |
| title_short | Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor Drugs |
| title_sort | treatment for nontype 1 retinopathy of prematurity by intravitreal injection of antivascular endothelial growth factor drugs |
| url | http://dx.doi.org/10.1155/2022/6266528 |
| work_keys_str_mv | AT haitaozhang treatmentfornontype1retinopathyofprematuritybyintravitrealinjectionofantivascularendothelialgrowthfactordrugs AT xinyang treatmentfornontype1retinopathyofprematuritybyintravitrealinjectionofantivascularendothelialgrowthfactordrugs AT fangfangzheng treatmentfornontype1retinopathyofprematuritybyintravitrealinjectionofantivascularendothelialgrowthfactordrugs AT xiangkeyin treatmentfornontype1retinopathyofprematuritybyintravitrealinjectionofantivascularendothelialgrowthfactordrugs AT suhuawan treatmentfornontype1retinopathyofprematuritybyintravitrealinjectionofantivascularendothelialgrowthfactordrugs |